FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3082852593> ?p ?o ?g. }

• W3082852593 abstract "Breast cancer patients who have minimal residual disease (MRD) after surgery or systemic therapies are at a higher risk of relapse. The ability of MRD to efficiently switch between quiescence and proliferation, depending upon the challenges in the body, increases likelihood of relapse. With the goal of developing therapies that would halt the progression of MRD to clinical metastases, we have developed a cell culture model of such poor prognosis MRD. The model involves choosing cancer cell lines established from therapy-resistant breast cancers, such as inflammatory breast cancer, and subjecting them to glutamine deficiency to select progenitor-like cancer cells that are highly resistant, and which can metastasize to multiple organs in nude mice. Investigations of these adaptable cells (functional studies and molecular analyses) have revealed a variety of ways (genetic mutations, modifications of epigenome, transcriptome, proteome, etc.) that generate a tremendous cellular heterogeneity, and confer survival advantages under various bottlenecks in the body. For a potential therapy to be suitable at the MRD stage, it must be safe (an important criterion prior to clinical relapse), immune system-friendly, and disrupt heterogeneous progenitor-like cancer cells that evolve into clinical metastases. Here we evaluated two ribonucleoside analogs, namely 6-mercaptopurine (6-MP) and 5-azacitidine (5-AzaC), because of their potential to disrupt transcriptome and epigenome in MRD. We chose low-dose 6-MP based on its ability to induce and maintain remission in inflammatory bowel disease (IBD) and childhood acute lymphoblastic leukemia (both situations requiring a control of abnormal progenitor cells), for evaluation in our model of adaptable SUM149-MA cells (MA for metabolic adaptability). A long treatment with low-dose 6-MP inhibited progenitor-like cancer cells from proliferating thus keeping them arrested in quiescence. Here we found that that long treatment with 1 µM 5-AzaC, without a significant effect on cell proliferation, sensitized cancer cells to inhibitory effects of low dose 6-MP (1 µM). Importantly, the treatments for several weeks with low doses of 6-MP and/or 5-AzaC did not render cancer cells resistant to chemotherapeutic drugs doxorubicin or paclitaxel. In fact the cells became more sensitive to chemotherapeutic drugs upon treatment with 6-MP and/or 5-AzaC. Our analyses of protein markers of epithelial-to-mesenchymal transition (EMT) indicated that treatments with 6-MP and/or 5-AzaC do not significantly reverse EMT in our system. Our results suggest that safe and effective drugs like 6-MP (singly or combined with 5-AzaC) could halt progression of poor-prognosis MRD toward recurrence/metastasis. In addition to the direct effects on poor prognosis MRD, 6-MP could potentially modulate the immune system towards a healthy state (analogous to what it does in IBD), to control MRD. An immune modulator like 6-MP could also potentially limit autoimmune reaction type severe toxicities associated with immune checkpoint blockade therapies, thus improving their efficacy in eradicating cancer. Supported by a State of Texas Grant for Rare and Aggressive Cancers.Citation Format: Balraj Singh, Vanessa N. Sarli, Anthony Lucci. Potential of 6-mercaptopurine and 5-azacitidine in halting progression of poor prognosis residual disease in triple negative breast cancer [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 2751." @default.
• W3082852593 created "2020-09-08" @default.
• W3082852593 creator A5004443463 @default.
• W3082852593 creator A5042475462 @default.
• W3082852593 creator A5081006682 @default.
• W3082852593 date "2020-08-13" @default.
• W3082852593 modified "2023-10-18" @default.
• W3082852593 title "Abstract 2751: Potential of 6-mercaptopurine and 5-azacitidine in halting progression of poor prognosis residual disease in triple negative breast cancer" @default.
• W3082852593 doi "https://doi.org/10.1158/1538-7445.am2020-2751" @default.
• W3082852593 hasPublicationYear "2020" @default.
• W3082852593 type Work @default.
• W3082852593 sameAs 3082852593 @default.
• W3082852593 citedByCount "0" @default.
• W3082852593 crossrefType "proceedings-article" @default.
• W3082852593 hasAuthorship W3082852593A5004443463 @default.
• W3082852593 hasAuthorship W3082852593A5042475462 @default.
• W3082852593 hasAuthorship W3082852593A5081006682 @default.
• W3082852593 hasConcept C104317684 @default.
• W3082852593 hasConcept C117717151 @default.
• W3082852593 hasConcept C121608353 @default.
• W3082852593 hasConcept C126322002 @default.
• W3082852593 hasConcept C143998085 @default.
• W3082852593 hasConcept C150194340 @default.
• W3082852593 hasConcept C190727270 @default.
• W3082852593 hasConcept C201750760 @default.
• W3082852593 hasConcept C203014093 @default.
• W3082852593 hasConcept C2778461978 @default.
• W3082852593 hasConcept C2779823535 @default.
• W3082852593 hasConcept C2780110267 @default.
• W3082852593 hasConcept C2780839634 @default.
• W3082852593 hasConcept C28328180 @default.
• W3082852593 hasConcept C502942594 @default.
• W3082852593 hasConcept C530470458 @default.
• W3082852593 hasConcept C54355233 @default.
• W3082852593 hasConcept C60644358 @default.
• W3082852593 hasConcept C71924100 @default.
• W3082852593 hasConcept C86803240 @default.
• W3082852593 hasConceptScore W3082852593C104317684 @default.
• W3082852593 hasConceptScore W3082852593C117717151 @default.
• W3082852593 hasConceptScore W3082852593C121608353 @default.
• W3082852593 hasConceptScore W3082852593C126322002 @default.
• W3082852593 hasConceptScore W3082852593C143998085 @default.
• W3082852593 hasConceptScore W3082852593C150194340 @default.
• W3082852593 hasConceptScore W3082852593C190727270 @default.
• W3082852593 hasConceptScore W3082852593C201750760 @default.
• W3082852593 hasConceptScore W3082852593C203014093 @default.
• W3082852593 hasConceptScore W3082852593C2778461978 @default.
• W3082852593 hasConceptScore W3082852593C2779823535 @default.
• W3082852593 hasConceptScore W3082852593C2780110267 @default.
• W3082852593 hasConceptScore W3082852593C2780839634 @default.
• W3082852593 hasConceptScore W3082852593C28328180 @default.
• W3082852593 hasConceptScore W3082852593C502942594 @default.
• W3082852593 hasConceptScore W3082852593C530470458 @default.
• W3082852593 hasConceptScore W3082852593C54355233 @default.
• W3082852593 hasConceptScore W3082852593C60644358 @default.
• W3082852593 hasConceptScore W3082852593C71924100 @default.
• W3082852593 hasConceptScore W3082852593C86803240 @default.
• W3082852593 hasLocation W30828525931 @default.
• W3082852593 hasOpenAccess W3082852593 @default.
• W3082852593 hasPrimaryLocation W30828525931 @default.
• W3082852593 hasRelatedWork W10138567 @default.
• W3082852593 hasRelatedWork W12293262 @default.
• W3082852593 hasRelatedWork W15103610 @default.
• W3082852593 hasRelatedWork W16537264 @default.
• W3082852593 hasRelatedWork W17538324 @default.
• W3082852593 hasRelatedWork W18725558 @default.
• W3082852593 hasRelatedWork W19676875 @default.
• W3082852593 hasRelatedWork W3971684 @default.
• W3082852593 hasRelatedWork W5387012 @default.
• W3082852593 hasRelatedWork W7194512 @default.
• W3082852593 isParatext "false" @default.
• W3082852593 isRetracted "false" @default.
• W3082852593 magId "3082852593" @default.
• W3082852593 workType "article" @default.